Biotech Analyst Harrison provides an IP trial lawyer’s perspective on the ongoing Liquidia (LQDA) v. United Therapeutics (UTHR) litigation on an Analyst/Industry conference call to be held on October 7 at 11 am.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia Technologies: Promising Growth and Market Expansion with Yutrepia
- Liquidia Technologies call volume above normal and directionally bullish
- Liquidia Technologies put volume heavy and directionally bearish
- United Therapeutics price target raised to $463 from $314 at BofA
- Liquidia Technologies’ Earnings Call Highlights YUTREPIA Success